Propanc Biopharma (NASDAQ:PPCB) is drawing attention to the therapeutic promise of its lead candidate, PRP, an investigational proenzyme treatment aimed at tackling metastatic cancer arising from solid tumors—particularly aggressive, poorly differentiated forms associated with poor patient outcomes.
Pancreatic cancer remains among the most lethal malignancies, with a five-year survival rate of just 13%, compared to an overall cancer survival rate near 70%. Despite incremental advances, existing therapies—including chemotherapy, targeted agents and newer treatment modalities—have delivered limited progress, often accompanied by significant toxicity and the development of drug resistance.
PRP is designed to offer a differentiated approach. Administered intravenously, the therapy targets cancer stem cells, which are believed to drive tumor growth and recurrence. It also aims to inhibit metastasis by suppressing epithelial-mesenchymal transition (EMT), alter the tumor microenvironment, reduce angiogenesis and enhance tumor sensitivity to chemotherapy.
According to preclinical findings, PRP demonstrated more than 85% inhibition of tumor growth in pancreatic cancer models. The company also reported reductions in fibrosis and markers of drug resistance, alongside a more favorable safety profile compared with conventional cytotoxic treatments. In a small compassionate-use study involving advanced-stage patients, survival reportedly increased from approximately 5.6 months to 9 months.
Differentiated Mechanism Versus Standard Therapies
Propanc positions PRP as a complementary strategy to existing cancer treatments:
- Chemotherapy: PRP may improve responsiveness in resistant tumors, potentially enabling lower doses and reduced side effects.
- Targeted therapies: Rather than focusing on single genetic mutations, PRP is designed to address cancer stem cells and metastatic spread more broadly.
- Immunotherapy: By reshaping the tumor microenvironment, PRP may help convert immunologically “cold” pancreatic tumors into forms more responsive to immune-based treatments.
The company is preparing to initiate a Phase 1b First-In-Human clinical trial in 2026. The program is supported by recent capital raises, expanded intellectual property protection and Orphan Drug designation from the U.S. Food and Drug Administration for pancreatic cancer.
With limited effective options currently available for metastatic pancreatic disease, Propanc believes PRP could represent a novel, lower-toxicity therapeutic avenue if clinical results validate its early promise.